In recent years there has been an increase in multi-drug resistance (MDR) amongst gram-negative pathogens. This has impacted both hospital and community acquired infections.
The MICRONAUT-S MDR MRGN Screening plate provides an extended spectrum of critically important back-up antibiotics and meropenem screening concentrations for an improved detection of OXA-48-like type D carbapenemases.
It also offers an extended spectrum of antibiotics by introduction of the novel antibiotic combinations ceftazidime-avibactam and ceftolozane-tazobactam.
The MICRONAUT-S MDR MRGN Screening plate offers a range of features and benefits relating to the phenotypic detection of clinically relevant resistance mechanisms.
Please contact your local representative for availability in your country.
Not for sale in the USA. MERLIN Gesellschaft für mikrobiologische Diagnostika mbH – A Bruker Company (www.merlin-diagnostika.de)
As of May 2021, Bruker Daltonik GmbH is now Bruker Daltonics GmbH & Co. KG.